In mouse lung cancer models, EZH2 inhibitors (such as Tazemetostat) can significantly reduce H3K27me3 levels, relieve the epigenetic silencing of antigen presentation genes, and synergize with PD-1/PD-L1 immune checkpoint inhibitors, suggesting the potential of combining epigenetic therapy with immunotherapy (200). Here, CD274 is linked to lung cancer.